Abstracts tagged "B cells"

Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 858 • 2014 ACR/ARHP Annual Meeting
ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets
Li Chun Wang¹, Stuart Perper¹, Annette Schwartz², Christian Goess³, Liz O'connor⁴, Dawna Hartman², Candace Graff², Andrew Souers⁵, Joel Leverson⁵, Steven Elmore⁵ and Lisa Olson², ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, North Chicago, IL
Background/Purpose Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. Navitoclax, a selective inhibitor of both BCL-2 and BCL-X(L) demonstrated…
Abstract Number: 2185 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2
Brendan M. Giles¹ and Susan A. Boackle², ¹University of Colorado School of Medicine, Aurora, CO, ²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: We have recently identified a variant in intron 1 of complement receptor 2 (CR2/CD21) that is associated with decreased risk of lupus (rs1876453; Pmeta=4.2×10-4,…
Abstract Number: 1718 • 2014 ACR/ARHP Annual Meeting
B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis
Sébastien Sanges^1,2,3, Niloufar Kavian⁴, Carine Hauspie^1,3,5, Carole Nicco⁴, Thomas Guerrier^1,3, Virginie Dutoit-Lefèvre^1,3, Guillaume Lefèvre^1,2,5,6, Alexandra Forestier^1,2,3, Vincent Sobanski^1,2,6, Christelle Faveeuw⁷, Myriam Labalette^1,3,5, Frédéric Batteux⁴, David Launay^1,2,3 and Sylvain Dubucquoi^1,3,5, ¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³EA 2686, Lille, Lille, France, ⁴Université Paris Descartes, EA 1833, Hôpital Cochin, AP-HP, Paris, Paris, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶EA 2686, Lille, LILLE, France, ⁷Institut National de la Santé et de la Recherche Médicale Unité 547, Institut Pasteur de Lille, Institut Fédératif de Recherche 142, Université de Lille Nord de France, Lille, France
Background/Purpose Systemic sclerosis (SSc) is a multi-organ fibrotic disease associated with auto-immune abnormalities. Several clinical and experimental observations suggest that B cells are involved in…
Abstract Number: 756 • 2014 ACR/ARHP Annual Meeting
Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells
Ayumi Yoshizaki¹, Yoshihide Asano², Takashi Taniguchi¹, Ryosuke Saigusa¹, Kouki Nakamura¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Zenshiro Tamaki¹, Miki Miyazaki¹ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose Nucleosome is the basic repeating units of chromatin. Each nucleosome is composed of an inner core of histones H3 and H4 and an outer…
Abstract Number: 1951 • 2014 ACR/ARHP Annual Meeting
A Novel CD27^(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE
Sarah Fleischer¹, Claudia Giesecke¹, Henrik Mei¹, Peter E. Lipsky², Capucine Daridon³ and Thomas Dörner³, ¹Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany, Berlin, Germany, ²Peking Union Medical College Hospital, Beijing, China, ³CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease known to be associated with a breakdown of self-tolerance, B-cell hyperactivity and disturbed B-cell homeostasis of…
Abstract Number: 1623 • 2014 ACR/ARHP Annual Meeting
Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus
Julie Ducreux¹, Séverine Nieuwland², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: systemic lupus erythematosus (SLE) is characterized by a break of tolerance to autoantigens, and polyclonal activation of B cells. We performed multicolor flow cytometry…
Abstract Number: 662 • 2014 ACR/ARHP Annual Meeting
Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus
Amanda Watkins¹, Ramon Bonegio², Guneet Kochar¹, Gabriella Wilson¹, Bari Laskow¹, Christophe Richez¹, Ian Rifkin¹ and Kei Yasuda³, ¹Boston University School of Medicine, Boston, MA, ²Renal, Boston University School of Medicine, Boston, MA, ³Medicine, Boston University School of Medicine, Boston, MA
Background/Purpose Interferon regulatory factor 5 (IRF5) polymorphisms are strongly associated with an increased risk of developing Systemic Lupus Erythematosus (SLE). SLE is caused, in part,…
Abstract Number: 1742 • 2013 ACR/ARHP Annual Meeting
Effects Of Blisibimod, An Inhibitor Of B Cell Activating Factor, On Serum Immunoglobulins and Infection Risk In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on IgG, IgM and infection risk in patients…
Abstract Number: 924 • 2013 ACR/ARHP Annual Meeting
B Cell Subsets and Dysfunction Of Regulatory B Cells In IgG4-Related Diseases and Primary Sjögren Syndrome: The Similarities and Differences
Wei Lin¹, Lixia Jin², Wen Zhang¹, Hua Chen³, QingJun Wu⁴, Yunyun Fei¹, Yan Zhao¹, Xiaofeng Zeng⁵ and Fengchun Zhang³, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Tsinghua University, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: IgG4 related disease (IgG4-RD) is a chronic, multisystem-involved autoimmune disease. Abnormally activated and differentiated B cells may play important roles. Regulatory B cells (Breg)…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 1743 • 2013 ACR/ARHP Annual Meeting
Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study
Barbara Sullivan¹, Wayne H. Tsuji², Vishala L. Chindalore³, Thomas D. Geppert⁴, Alla Rudinskaya⁵, Patricia Pardo⁶, Alan Kivitz⁷, C. Michael Neuwelt⁸, Meggan Mackay⁹, R. John Looney¹⁰, J. Carter Thorne¹¹, Marilee Andrew¹², Greg Arnold¹³, Michael Boedigheimer¹, Kit Chiu¹, Cherie Green¹, Arunan Kaliyaperumal¹, Christine Wang¹⁴, Andrew Welcher¹ and James Chung¹, ¹Amgen, Thousand Oaks, CA, ²Clinical Research/Inflammation, Amgen, Seattle, WA, ³Anniston Medical Clinic PC, Anniston, AL, ⁴Metroplex Clinical Research Center, LLC, Dallas, TX, ⁵Danbury Hospital, Danbury, CT, ⁶MRA Clinical Research, Miami, FL, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸East Bay Rheumatology Research Institute, San Leandro, CA, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Amgen, Seattle, WA, ¹³Medical Sciences, Amgen, Thousand Oaks, CA, ¹⁴Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: The interaction of inducible costimulator (ICOS) with its ligand, B7-related protein-1 (B7RP-1 or ICOSL), plays a role in T cell differentiation, cytokine production, and…
Abstract Number: 890 • 2013 ACR/ARHP Annual Meeting
Quantitative Cell Distance Mapping In Human Nephritis Reveals Organization Of In Situ Adaptive Immune Responses
Marcus R. Clark¹, Vladimir M. Liarski¹, Natalya Kavernia², Maryellen L. Giger³, Anthony Chang⁴, Yahui Peng³ and Daniel F. Brandt², ¹Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²Rheumatology, University of Chicago, Chicago, IL, ³Radiology, University of Chicago, Chicago, IL, ⁴Pathology, University of Chicago, Chicago, IL
Background/Purpose: Inflammatory infiltrates contain multiple cell types that could interact in myriad ways to amplify in situ immune responses. However, there currently are no methods…
Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…
Abstract Number: 172 • 2013 ACR/ARHP Annual Meeting
Transcript Profiling Of Kidney Biopsies From Chinese Patients With Lupus Nephritis Suggests a Prevalence Of Infiltrating CD8+ T Cells, Monocytes/Macrophages, and B Cells In ISN/RPS Class IV Disease
Zheng Liu¹, Chris Morehouse¹, Xinfang Huang², Philip Brohawn¹, Nan Shen³, Gabor G. Illei⁴, Yihong Yao¹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ³Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, cincinnati, OH, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD
Transcript profiling of kidney biopsies from Chinese patients with lupus nephritis suggests a prevalence of infiltrating CD8+ T cells, monocytes/macrophages, and B cells in ISN/RPS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].